It is partially attributed to insufficiency of TILs infiltration, low expression of PD-1/PD-L1, and low tumor mutation burden (TMB) in gliomas (26), which are not conducive to the ICIs to revive the anti-tumor immune response. This evidence concerns the gene PDCD1 and central nervous system cancer.